Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly ...

Abivax (ABVX) stock cools as CEO denies talks between Eli Lilly (LLY) and the French government over U.S.-based pharma's ...

A case targeting alleged fraud around the safety risk of a blockbuster diabetes drug is leveraging the RICO pathway and could ...

NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an average annual return of 37.44%. Currently, Eli Lilly and Co has a market ...

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Eli Lilly has won U.S. Food and Drug Administration breakthrough -therapy designation for its sofetabart mipitecan drug candidate for certain patients with ovarian cancer.

Powerful new weight-loss medications are in the works to treat obesity. Doctors explain why more options are needed and the ...

Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format.

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...

The San Francisco-based drugmaker said Tuesday that it plans to double its investment and create an additional 100 jobs at a ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...